Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

240
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
240
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

139
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
139
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

223
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
223
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

322
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
322
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of ultraviolet germicidal irradiation (UVGI) devices to decrease the incidence of respiratory infections in nursing homes: study protocol for a cluster randomized crossover trial (RESPROTECT).

Trials·2026
Same author

Macrolide maintenance therapy in chronic inflammatory airway diseases: A survey of French pulmonologist's practices.

Respiratory medicine and research·2026
Same author

Post-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort.

The Lancet. Infectious diseases·2026
Same author

Evolution of characteristics and outcomes for patients hospitalized for COVID-19 during successive waves of the epidemic in France.

Annals of epidemiology·2026
Same author

Factors associated with severity of pulmonary tuberculosis in people living with and without HIV: a systematic review.

BMC infectious diseases·2026
Same author

Transbronchial lung cryobiopsy: a safe and effective technique in the diagnosis of interstitial lung disease in the older people.

BMC geriatrics·2026
Same journal

Value of the Pitt bacteremia score in predicting the outcome of non-bacteremic patients with infections caused by multidrug-resistant organisms.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same journal

Concurrent comparison of severity of influenza and COVID-19 among hospitalized patients in Hong Kong: a target trial emulation on observational healthcare data.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same journal

Lytic bacteriophages active in urine against multi-drug resistant clinically derived Klebsiella pneumoniae causing urinary tract infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same journal

Time to Recovery from Long COVID: A Longitudinal Analysis of Symptom Duration and Risk Factors Using Accelerated Failure Time Models.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same journal

Site matters: extrapulmonary tuberculosis localization patterns and clinical outcomes in the Netherlands,1993-2022.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same journal

When Institutional Transitions Interrupt Prevention: 3HP Tuberculosis Preventive Treatment Continuity in a Paraguayan Prison Cohort.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K

Rapid decrease in IL-1Ra and IP-10 plasma levels following tuberculosis treatment initiation.

Polidy Pean1, Roseline Affi2, Corine Chazalon3

  • 1Immunology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|May 13, 2024
PubMed
Summary
This summary is machine-generated.

Interleukin-1 receptor antagonist (IL-1Ra) plasma levels can quickly predict tuberculosis (TB) treatment response. Measuring IL-1Ra one week after starting TB treatment may help clinicians assess treatment effectiveness early.

Keywords:
BiomarkersHIVTreatment responseTuberculosis

More Related Videos

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.0K
Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

394

Related Experiment Videos

Last Updated: Jun 26, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.0K
Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

394

Area of Science:

  • Infectious Diseases
  • Immunology
  • Biomarker Discovery

Background:

  • Tuberculosis (TB) treatment monitoring requires tools for rapid prediction of outcomes.
  • Early assessment of TB treatment response is crucial for patient management and preventing drug resistance.

Purpose of the Study:

  • To evaluate if changes in innate immunity biomarkers within two weeks of TB treatment initiation can predict treatment response.
  • To assess the utility of plasma levels of IL-1Ra, IP-10, and CD163 as early indicators of TB treatment efficacy.

Main Methods:

  • A prospective proof-of-concept study (ANRS12394-LILAC-TB) enrolled adults with rifampicin-susceptible TB in Cambodia and Côte d'Ivoire.
  • Plasma biomarker concentrations (IL-1Ra, IP-10, CD163) were measured using enzyme-linked immunosorbent assay kits.
  • Longitudinal comparisons were performed using the Wilcoxon test for paired data.

Main Results:

  • A total of 55 patients were enrolled, with 83% achieving TB treatment success.
  • Plasma IL-1Ra levels significantly decreased by week 1 post-treatment initiation, irrespective of HIV status.
  • Plasma IP-10 levels also decreased significantly at weeks 1 and 2, though the reduction was less pronounced in HIV-positive participants.

Conclusions:

  • Plasma IL-1Ra levels show potential as an early biomarker for monitoring TB treatment response.
  • Measurement of IL-1Ra at baseline and one week after treatment initiation may aid clinicians in rapid assessment of TB treatment efficacy.
  • This approach could facilitate timely clinical decisions regarding TB treatment management.